Evidence map›Paper›PMID 41438698›Full record

ReviewFrontiers in surgery2025

Comparative efficacy and safety of teriparatide versus bisphosphonates in osteoporosis: a meta-analysis.

Huan Jin, Ying Dong, Cai Huang, Di Wang, Ziyi He, Lin Shen, Chen Ma, Zixian Wang, Siwei Shi, Bo Shuai

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Huan JinDepartment of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ying DongDepartment of Internal Medicine, Rongjun Hostipal of Hubei, Wuhan, China.
Cai HuangDepartment of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Di WangDepartment of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ziyi HeDepartment of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Lin ShenDepartment of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chen MaDepartment of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zixian WangDepartment of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Siwei ShiDepartment of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Bo ShuaiDepartment of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This meta-analysis systematically compared the efficacy and safety of teriparatide and bisphosphonates in treating osteoporosis (OP) to inform optimal treatment strategies. Methods: A comprehensive literature search was conducted in PubMed, Embase, Cochrane Library, Web of Science, and Google Scholar from inception through October 2024. Randomized controlled trials comparing teriparatide and bisphosphonates for OP were included. Primary outcomes included vertebral/non-vertebral fracture risk reduction and lumbar spine/femoral neck bone mineral density (BMD) improvements. Data were analyzed using RevMan 5.3, with dichotomous data assessed via odds ratios (OR) and continuous data via mean differences (MD), both reported with 95% confidence intervals (CI). Results: Thirteen studies involving 4,420 patients were analyzed (six Grade A, four Grade B, three Grade C). Teriparatide significantly reduced vertebral [OR = 0.40, 95% CI = (0.33, 0.49), Conclusion: Teriparatide demonstrated superior efficacy in reducing vertebral/non-vertebral fracture risks and improving BMD in both short- and long-term treatments, with a safety profile comparable to bisphosphonates.

Indexed as

bisphosphonatesbone mineral densitymeta-analysisosteoporosisteriparatidevertebral fracture

Identifiers

PMID41438698
PMCPMC12719462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.